Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
MaxCyte, Inc. (MXCT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.39-4.79%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for MXCT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Stabilize leadership and improve cost structure | A new CFO was hired to improve management. | Intact | Leadership instability or rising costs persist beyond 1 year | Leadership stable (CFO hired Mar 2026); costs controlled (Q3 rev beat, guidance raised) CFO appointed March 2026. Q3 2026 revenue beat expectations, leading to raised full-year guidance. No signs of cost escalation or leadership turnover. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 10, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth business, not a proven durable compounder, because it remains loss-making. The long-term thesis is intact, with recent results in the stronger half of its industry and management making progress on revenue goals.
MXCT trades at a substantial premium to peers, while the model shows expectations slightly below its estimate of fundamentals. The valuation is tagged as justified, with low fragility, but the premium leaves the thesis reliant on continued execution.
Near term, preliminary Q3 results showed core revenue growth of 26% year over year, and management raised full-year revenue guidance to about $34 million from its earlier $30–32 million range. Cash and investments were $141.9 million at Q2, while the company had repurchased about $5.5 million under its $10 million program; the cash goal is still marked mixed. Losses and elevated risk remain, and a guidance cut would be a meaningful setback.
Over the next few quarters, the key test is whether MXCT delivers on its raised revenue outlook and maintains its cash position. A weakening jobs trend could increase recession concerns for cyclical businesses, while continued strong results and guidance from major Healthcare companies could support the sector backdrop. The evidence on the June legal and regulatory event is thin, so its ongoing importance is unclear.
For the 1–3 year view, recent operating progress keeps the thesis intact, but the loss-making business and premium valuation make execution and risk management important swing factors. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in MaxCyte, Inc.'s published investment case. The stated target is Maintain bid price above $1 for 30 days. |
| Under Pressure |
| Closing bid price stays below $1 for 30 consecutive days |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve 2026 revenue of $30-32 million | A primary condition in MaxCyte, Inc.'s published investment case. The stated target is $30-32 million. | Intact | Full-year 2026 revenue falls below $30 million | Revenue: $7.271M FY2026-Q2; GAAP. Published target: $30-32 million. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 20267,271,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “ Full Year 2026 Guidance · Full year revenue expected to be $30 million to $32 million consisting of: o Core revenue of $25 million to $27 million.” “In the first half of 2026, we delivered a meaningful reduction in net loss and expect to benefit further as we continue to execute against our plan and return to revenue growth.”” Revenue was $9.651 million in 2026-Q1. Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.25 → $-0.26 · observed estimates
$0.04B → $0.04B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.25 | $37,097,500 | 3 / 4 |
| 2026-07-25 | $-0.25 | $37,097,500 | 3 / 4 |
| 2026-07-26 | $-0.25 | $37,097,500 | 3 / 4 |
| 2026-07-27 | $-0.25 | $37,097,500 | 3 / 4 |
| 2026-07-28 | $-0.25 | $37,097,500 | 3 / 4 |
| 2026-07-29 | $-0.23 | $37,091,030 | 4 / 6 |
| 2026-07-30 | $-0.23 | $37,091,030 | 4 / 6 |
| 2026-07-31 | $-0.23 | $37,091,030 | 4 / 6 |
| 2026-08-01 | $-0.24 | $37,094,533 | 3 / 4 |
| 2026-08-02 | $-0.23 | $37,091,030 | 4 / 6 |
| 2026-08-03 | $-0.23 | $37,091,030 | 4 / 6 |
| 2026-08-04 | $-0.23 | $37,091,030 | 4 / 6 |
| 2026-08-05 | $-0.24 | $37,094,533 | 3 / 4 |
| 2026-08-06 | $-0.24 | $37,094,533 | 3 / 4 |
| 2026-08-07 | $-0.24 | $37,094,533 | 3 / 4 |
| 2026-08-08 | $-0.23 | $37,091,030 | 4 / 6 |
| 2026-08-09 | $-0.23 | $37,091,030 | 4 / 6 |
| 2026-08-10 | $-0.23 | $37,091,030 | 4 / 6 |
| 2026-08-12 | $-0.23 | $37,091,030 | 4 / 6 |
| 2026-08-13 | $-0.23 | $37,091,030 | 4 / 6 |
| 2026-08-14 | $-0.24 | $37,094,533 | 3 / 4 |
| 2026-08-15 | $-0.24 | $37,094,533 | 3 / 4 |
| 2026-08-16 | $-0.24 | $37,094,533 | 3 / 4 |
| 2026-08-17 | $-0.24 | $37,094,533 | 3 / 4 |
| 2026-08-18 | $-0.24 | $37,094,533 | 3 / 4 |
| 2026-08-19 | $-0.24 | $37,094,533 | 3 / 4 |
| 2026-08-20 | $-0.26 | $37,171,833 | 3 / 4 |
| 2026-08-21 | $-0.26 | $37,171,833 | 3 / 4 |
| 2026-08-22 | $-0.26 | $37,406,200 | 3 / 4 |
| 2026-08-23 | $-0.26 | $37,406,200 | 3 / 4 |
| 2026-08-24 | $-0.26 | $37,406,200 | 3 / 4 |
| 2026-08-25 | $-0.26 | $37,406,200 | 3 / 4 |
| 2026-08-26 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-08-27 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-08-28 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-08-29 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-08-30 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-08-31 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-01 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-02 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-03 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-04 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-05 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-06 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-07 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-08 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-09 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-10 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-11 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-12 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-13 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-14 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-15 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-16 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-17 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-18 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-19 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-20 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-21 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-22 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-23 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-24 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-25 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-26 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-27 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-28 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-29 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-09-30 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-10-01 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-10-02 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-10-03 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-10-04 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-10-05 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-10-06 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-10-07 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-10-08 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-10-09 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-10-10 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-10-11 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-10-12 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-10-13 | $-0.27 | $37,180,167 | 3 / 4 |
| 2026-10-14 | $-0.27 | $37,213,500 | 3 / 4 |
| 2026-10-15 | $-0.27 | $37,208,333 | 3 / 4 |
| 2026-10-16 | $-0.27 | $37,225,000 | 3 / 4 |
| 2026-10-17 | $-0.27 | $37,225,000 | 3 / 4 |
| 2026-10-18 | $-0.26 | $37,229,667 | 3 / 4 |
| 2026-10-19 | $-0.26 | $37,229,667 | 3 / 4 |
| 2026-10-20 | $-0.26 | $37,229,667 | 3 / 4 |
| 2026-10-21 | $-0.26 | $37,229,667 | 3 / 4 |
| 2026-10-22 | $-0.26 | $37,229,667 | 3 / 4 |
| 2026-10-23 | $-0.26 | $37,229,667 | 3 / 4 |
| 2026-10-24 | $-0.26 | $37,229,667 | 3 / 4 |
| 2026-10-25 | $-0.26 | $37,234,833 | 3 / 4 |
| 2026-10-26 | $-0.26 | $37,234,833 | 3 / 4 |
| 2026-10-27 | $-0.26 | $37,234,833 | 3 / 4 |
| 2026-10-28 | $-0.26 | $37,234,833 | 3 / 4 |
| 2026-10-29 | $-0.26 | $37,234,833 | 3 / 4 |
| 2026-10-30 | $-0.26 | $37,234,833 | 3 / 4 |
| 2026-10-31 | $-0.26 | $37,234,833 | 3 / 4 |
| 2026-11-01 | $-0.26 | $37,234,833 | 3 / 4 |
| 2026-11-02 | $-0.26 | $37,234,833 | 3 / 4 |
| 2026-11-03 | $-0.26 | $37,234,833 | 3 / 4 |
| 2026-11-04 | $-0.26 | $37,234,833 | 3 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.